News Release

Results of study could be biggest rehab advance in decades for patients after stroke

Patients who incorporated vagus nerve simulation during physical or occupational therapy showed 2-3 times the improvement in arm and hand function

Peer-Reviewed Publication

MGH Institute of Health Professions

Dr. Teresa Kimberley with a patient and grad student

image: Dr. Teresa Kimberley (left) works with a vagus nerve stimulation patient (center) and a grad assistant at the Brain Recovery Lab on the MGH Institute of Health Professions campus in Boston. view more 

Credit: John Shaw

Results of a study co-authored by MGH Institute of Health Professions researcher Teresa Kimberley, PhD, PT, have the potential to be one of the most impressive advances in decades to help improve the lives of patients who have had a stroke with resulting arm weakness.

In an article published April 22 in The Lancet, "Vagus Nerve Stimulation Paired with Rehabilitation for Upper Limb Motor Function After Ischaemic Stroke (VNS-REHAB): A Randomised, Blinded, Pivotal, Device Trial," the study reports that patients who incorporated vagus nerve stimulation during physical or occupational therapy showed 2 to 3 times the improvement in arm and hand function compared to those who received intense rehabilitation with sham stimulation.

"How to optimize recovery after a stroke has been studied for decades, but there has been little shown to dramatically improve peoples' daily lives," said Dr. Kimberley, who is a senior author on both the pilot and pivotal vagus nerve stimulation studies, directs the MGH Institute's Brain Recovery Lab, and is a professor of physical therapy at the Boston health sciences graduate school. "Using vagus nerve stimulation paired with repetitions of therapeutic movement appears to help 'rewire' the brain to strengthen the brain pathways needed to perform the everyday tasks people want to be able to do. This may be an important new tool to improve people's lives."

The 108 patient participants in the study were implanted with a VNS system called Vivistim, produced by MicroTransponder, Inc., an Austin-based, privately held medical device development company, which funded the study. During six weeks of in-clinic therapy followed by three months of home-based therapy, participants received a stimulation of the vagus nerve via a small electrical pulse from a cuff wrapped around the nerve, powered by a unit implanted under the skin near the clavicle. This pulse, delivered during their rehabilitation exercises, essentially helps the brain relearn how to perform tasks such as carrying a grocery bag, using a fork, or casting a fishing line.

Participants in the trial ranged from nine months to 10 years post-stroke. With 50%-60% of the 658,000 yearly stroke survivors in the United States being left with upper extremity motor deficits that persist for months or years, the findings suggest they may be able to improve function and perform some everyday tasks once again.

The study reported there were no unexpected or serious adverse events associated with the Vivistim system.

Kimberley, who has an appointment as research staff at Massachusetts General Hospital Department of Neurology and as core faculty in the hospital's Center for Neurotechnology and Neurorecovery, acknowledges the large team effort associated with running this trial, which would not have been possible without the multidisciplinary coordination provided by CNTR and the collaborative effort between the MGH Institute, MGH Neurology, and MGH Neurosurgery.

"We are only beginning to understand how to best stimulate the brain to regain function," said Kimberley, who has researched various types of brain stimulation for over 15 years. "Rehabilitation has always been the key to maximizing recovery after a stroke. Brain stimulation, including methods such as vagus nerve stimulation, may make rehabilitation activity even more impactful and lead to greater gains than we previously thought possible for people with neurologic disorders."

###

The Vivistim system currently is being reviewed by the U.S. Food and Drug Administration and by regulatory agencies in the United Kingdom and European Union.

Dr. Kimberley can be reached at 612-382-8036 or tkimberley@mghihp.edu.

Read The Lancet article.

Read The Lancet editorial.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.